Hipotiroid hastalarda plazma visfatin konsantrasyonlarının tiroid otoimmünitesi ve ateroskleroz ile ilişkisi

Amaç: Visfatin/pre-B cell enhancement factor; insülin direnci, diyabet, dislipidemi, inflamasyon, otoimmun hastalıklar ve ateroskleroz patogeneziyle ilişkili adipoz dokudan salınan TNF-alfa ve IL-6 gibi inflamatuar sitokinlerin yapımını uyarır. Bu çalışmada amacımız otoimmün hipotiroidizmli hastalarda plazma visfatin düzeyi ve bunun tiroid otoimmünitesi ve ateroskleroz ile ilişkisini değerlendirmektir.Gereç ve Yöntem: Çalışmamıza 35 yeni tanı almış Hashimoto hipotiroidili olgu (32 kadın/3 erkek, ort. yaş 43.8±9.6) ve 18 sağlıklı kontrol (17 kadın/1 erkek, ort. yaş 43.3±5.2) dahil edildi. Tiroid hormon replasmanı öncesi ve sonrası antropometrik ölçümler, karotid intima-media kalınlığı (KİMK), serum anti-Tg, anti-TPO, hsCRP, homosistein, lipo(a), ApoA, ApoB1, β-2 mikroglobulin, insulin, glukoz, visfatin, IL6, TNF-α, okside-LDL, lenfosit subgrupları ve lipid profile ölçümleri yapıldı. Serum visfatin konsantrasyonları ELİSA yöntemiyle çalışıldı.Bulgular: Serum visfatin konsantrasyonları otoimmün hipotiroidizm grubu ile kontrol grubu arasında benzerdi (6.29 ± 1.63 ng/ml to 6.36 ± 1.51 ng/ml, p>0.05), tiroid otoimmünitesi ve ateroskleroz belirteçleriyle korelasyonu saptanmadı. Tedavi öncesi ve sonrası hipotiroidi hastalarının plazma visfatin, okside LDL, IL-6 ve TNF-α konsantrasyonları ile sağlıklı kontrol grubu arasında istatiksel farklılık görülmedi. Sistolik ve diyastolik kan basıncı, HOMA-IR, trigliserid, Apo B and ApoB/ApoA, homosistein, β-2 mikroglobulin, KİMK gibi kardiyovasküler risk faktörleri hasta grubunda yüksek olarak bulundu. Okside-LDL, kolesterol, homosistein ve proteinuria konsantrasyonları anti-Tg ile pozitif korele idi. Sonuç: Serum visfatin konsantrasyonları ile tiroid otoimmünitesi ve ateroskleroz arasında ilişki bulunmadı.

Anahtar Kelimeler:

Visfatin, otoimmüne hipotiroidi, ateroskleroz

Plasma visfatin concentrations in hypothyroid patients and its relationship with thyroid autoimmunity and atherosclerosis

Aim: Visfatin/pre-B cell enhancement factor stimulates the production of inflammatory cytokines released from adipose tissue such as TNF-α and IL-6, which are shown to be related to the pathogenesis of insulin resistance, diabetes, dyslipidemia, inflammation, autoimmune diseases, and atherosclerosis. Our aim was to evaluate plasma visfatin concentrations in patients with autoimmune hypothyroidism and its relationship with thyroid autoimmunity and atherosclerosis.Material and Method: Thirty-five patients with newly diagnosed Hashimoto’s thyroiditis (32 women/3 men, mean age 43.8±9.6 years) and 18 healthy controls (17 women/1 men, mean age 43.3±5.2 years) were enrolled in the study. Anthropometric measurements, carotid intima-media thickness (CIMT), serum anti-Tg, anti-TPO, hsCRP, homocysteine, lipo(a), ApoA, ApoB1, β-2 microglobulin, insulin, glucose, visfatin, IL6, TNF-α, oxidized-LDL concentrations, lymphocyte subgroups and lipid profile were investigated both before and after thyroid hormone replacement therapy. Serum visfatin concentrations were determined by enzyme-linked immunosorbent assay (ELISA).Results: Mean serum visfatin concentrations were similar between autoimmune hypothyroidism group and control group (6.29 ± 1.63 ng/ml to 6.36 ± 1.51 ng/ml, p>0.05) and it was not correlated with thyroid autoimmunity and atherosclerosis markers. Plasma visfatin, oxidized LDL, IL-6, and TNF-α concentrations did not differ statistically between the control group and hypothyroid patients both before and after the therapy. The cardiovascular risk factors for systolic and diastolic blood pressure, HOMA-IR index, triglyceride, Apo B and ApoB/ApoA, homocysteine, β-2 microglobulin, and CIMT were found to be elevated in patients. Ox-LDL, cholesterol, homocysteine, and proteinuria concentrations were positively correlated with anti-Tg concentrations. Conclusion: Serum visfatin concentrations were not associated with thyroid autoimmunity and atherosclerosis.

Keywords:

Visfatin, autoimmune hypothyroidism, atherosclerosis,

PDF

___

1. Pearce EN, Farwell AP, Braverman LE (2003) Thyroiditis. The New England Journal of Medicine 348: 2646–2655.
2. Nyirenda MJ, Clark DN, Finlayson AR, Read J, Elders A, et al. (2005) Thyroid disease and increased cardiovascular risk. Thyroid 15:718-724.
3. Luk T, Malam Z, Marshall JC (2006) Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 83:10-13.
4. T. B. Dahl, A. Yndestad, M. Skjelland, Cui L, Wang T, et al. (2007) Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115: 972–980.
5. T.B. Dahl, S. Holm, P. Aukrust, B. Halvorsen (2012) Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu. Rev. Nutr 32: 229–243.
6. F. Brentano, O. Schorr, C. Ospeltetal. (2007) Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis & Rheumatism 56: 2829–2839.
7. C. P. Chung, A.G.Long, J. F. Solusetal (2009) Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus 18: 799–806.
8. S. A. Ismail and S. A. Mohamed (2012) Serum concentrations of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity. British Journal of Dermatology 167: 436–439.
9. N. Cinar and A. Gurlek (2013) Association between novel adipocytokines adiponectin, vaspin, visfatin, and thyroid: an experimental and clinical update. Endocrine Connections 2 : 30–38.
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 :412-419.
11. Caixàs A, Tirado R, Vendrell J, Gallart L, Megía A (2009) Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalization of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters. Clin Endocrinol(Oxf) 71: 733-738.
12. Özkaya M, Sahin M, Cakal E ,Yuzbasioglu F, Sezer K, et al. (2009) Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. J Endocrinol İnvest 32: 435-439.
13. Han J, Zhang TO, Xiao WH, Chang CQ, Ai H (2012) Up-regulation of visfatin expression in subjects with hyperthyroidism and hypothyroidism is partially relevant to a nonlinear regulation mechanism between visfatin and tri-iodothyronine with various concentrations. Chinese Medical Journal 125: 874–881.
14. Sawicka-Gutaj N, Zybek-Kocik A, Klimowicz A, Kloska M, Mańkowska-Wierzbicka D, et al. (2016) Circulating Visfatin in Hypothyroidism Is Associated with Free Thyroid Hormones and Antithyroperoxidase Antibodies. Int J Endocrinol 2016: 7402469.
15. Nyirenda MJ, Clark DN, Finlayson AR, Read J, Elders A, et al. (2005) Thyroid disease and increased cardiovascular risk. Thyroid 15: 718-724. 16. Efstathiadou Z, Bitsis S, Milionis HJ, Kukuvitis A, Bairaktari ET, et al. (2001) Lipid profile in subclinical hypothyroidism: is L-thyroxine substitution beneficial? Eur J Endocrinol 145: 705-10.
17. Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, et al. (2008) Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 69: 878-8432.
18. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, et al. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86: 1930-1935.
19. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocełak P, et al. (2007) Serum concentration of visfatin in obese women. Metabolism 56 :1131-1134.
20. Liu SW, Qiao SB, Yuan J, Liu DQ (2009) Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 71: 202-207. 21. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, et al. (2006) Elevated plasma level of visfatin/pre-B cell colony enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91: 295-299.
22. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, et al. (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. Journal of Immunology 178: 1748–1758.
23. Han J, Zhang TO, Xiao WH, Chang CQ, Ai H (2012) Up-regulation of visfatin expression in subjects with hyperthyroidism and hypothyroidism is partially relevant to a nonlinear regulation mechanism between visfatin and tri-iodothyronine with various concentrations. Chinese Medical Journal 125: 874–881.
24. Celik I, Akalin S, Erbas T. (1995) Serum levels of interleukin 6 and tumor necrosis factor-a in hyperthyroid patients before and after propylthiouracil treatment. European Journal of Endocrinology 132: 668–672.
25. Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, et al. (2000) Serum concentrations of proinflammatory cytokines in Graves’ disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. European Journal of Endocrinology 143: 197–202.
26. Kita T, Kume N, Minami M Hayashida K, Murayama T, et al. (2001) Role of oxidized LDL in atherosclerosis. Ann N Y Acad Sci. 947: 199-205.
27. Berndt J, Kloting N. (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54: 2.
28. Dogru T, Sonmez A, Tasci I , Bozoglu E, Yilmaz MI, et al. (2007) Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired tolerance. Diabetes Res Clin Pract 76: 24-29.
29. O'Leary DH, Pollak JF (2002) Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol 90:18-21.
30. Hulthe J, Fagerberg B (2002) Circulating Oxidized LDL Is Associated With Subclinical Atherosclerosis Development and Inflammatory Cytokines (AIR Study). Arterioscler Thromb Vasc Biol. 22: 1162-1167.
31. Covas MI, Esquerda A, García-Rico A, Mahy N. (1992) Peripheral blood T-lymphocyte subsets in autoimmune thyroid disease. J Investig Allergol Clin Immunol 2:131-135.
32. A. R. Moschen, A.Kaser, B.Enrichetal, Mosheimer B, Theurl M, et al. (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. The Journal of Immunology 178: 1748–1758.